| Date | Name | Title | Type | Security | Shares | Price | Value | Ownership | Reported |
| 08/08/2023 | ANDERSON KERRII B | Director | Sale | Common Stock | 5k | $211.57 | $1.1M | | 08/08/2023 |
| 08/01/2023 | Wilkinson Peter J | SVP, Chief Accounting Officer | Payment of Exercise | Common Stock | 17 | $213.61 | $3.6k | | 08/01/2023 |
| 08/01/2023 | Wilkinson Peter J | SVP, Chief Accounting Officer | Exercise | Restricted Stock Unit | 56 | $0.00 | $0 | | 08/01/2023 |
| 06/30/2023 | Wilkinson Peter J | SVP, Chief Accounting Officer | Grant | Restricted Stock Unit | 3.1k | $0.00 | $0 | | 06/30/2023 |
| 06/30/2023 | Schroeder Mark S | EVP, Pres Diagnostics & COO | Grant | Restricted Stock Unit | 11.6k | $0.00 | $0 | | 06/30/2023 |
| 06/30/2023 | Summy Amy B. | EVP, Chief Marketing Officer | Grant | Restricted Stock Unit | 5.8k | $0.00 | $0 | | 06/30/2023 |
| 06/30/2023 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | Grant | Restricted Stock Unit | 3k | $0.00 | $0 | | 06/30/2023 |
| 06/30/2023 | EISENBERG GLENN A | CFO, EVP | Grant | Restricted Stock Unit | 20.2k | $0.00 | $0 | | 06/30/2023 |
| 06/30/2023 | Schechter Adam H | President & CEO | Grant | Restricted Stock Unit | 73k | $0.00 | $0 | | 06/30/2023 |
| 06/30/2023 | BERBERIAN LANCE | EVP, CIO & CTO | Grant | Restricted Stock Unit | 7.8k | $0.00 | $0 | | 06/30/2023 |
| 06/30/2023 | van der Vaart Sandra D | EVP, Chief Legal Officer | Grant | Restricted Stock Unit | 6.2k | $0.00 | $0 | | 06/30/2023 |
| 06/30/2023 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | Grant | Restricted Stock Unit | 11.6k | $0.00 | $0 | | 06/30/2023 |
| 06/29/2023 | van der Vaart Sandra D | EVP, Chief Legal Officer | Sale | Common Stock | 212 | $240.00 | $50.9k | | 06/29/2023 |
| 06/06/2023 | Rothman Paul | Director | Grant | Restricted Stock Unit | 642 | $0.00 | $0 | | 06/06/2023 |
| 05/19/2023 | Kirchgraber Paul R | CEO, Covance Drug Development | Sale | Common Stock | 4.3k | $216.91 | $932.7k | | 05/19/2023 |
| 05/19/2023 | Kirchgraber Paul R | CEO, Covance Drug Development | Exercise | | 4.3k | $182.51 | $784.8k | | 05/19/2023 |
| 05/05/2023 | Schroeder Mark S | EVP, Pres Diagnostics & COO | Grant | | 1.4k | $223.86 | $313.4k | | 05/05/2023 |
| 05/05/2023 | Schroeder Mark S | EVP, Pres Diagnostics & COO | Grant | Restricted Stock Unit | 440 | $0.00 | $0 | | 05/05/2023 |
| 05/05/2023 | Bailey Megan D. | EVP, Chief Strategy Officer | Grant | Restricted Stock Unit | 180 | $0.00 | $0 | | 05/05/2023 |
| 05/05/2023 | Bailey Megan D. | EVP, Chief Strategy Officer | Grant | | 600 | $223.86 | $134.3k | | 05/05/2023 |
| 05/05/2023 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | Grant | | 1000 | $223.86 | $223.9k | | 05/05/2023 |
| 05/05/2023 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | Grant | Restricted Stock Unit | 300 | $0.00 | $0 | | 05/05/2023 |
| 05/05/2023 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | Grant | | 1.2k | $223.86 | $268.6k | | 05/05/2023 |
| 05/05/2023 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | Grant | Restricted Stock Unit | 370 | $0.00 | $0 | | 05/05/2023 |
| 03/31/2023 | Schroeder Mark S | EVP, Pres Diagnostics & COO | Sale | Common Stock | 3.9k | $225.81 | $880k | | 03/30/2023 |
| 03/30/2023 | Schroeder Mark S | EVP, Pres Diagnostics & COO | Grant | Common Stock | 6.8k | $0.00 | $0 | | 03/30/2023 |
| 03/30/2023 | Schroeder Mark S | EVP, Pres Diagnostics & COO | Payment of Exercise | Common Stock | 2.9k | $224.70 | $644k | | 03/30/2023 |
| 03/30/2023 | Kirchgraber Paul R | CEO, Covance Drug Development | Grant | Common Stock | 6.8k | $0.00 | $0 | | 03/30/2023 |
| 03/30/2023 | Kirchgraber Paul R | CEO, Covance Drug Development | Payment of Exercise | Common Stock | 2.9k | $224.70 | $648.5k | | 03/30/2023 |
| 03/30/2023 | Wilkinson Peter J | SVP, Chief Accounting Officer | Grant | Common Stock | 1.8k | $0.00 | $0 | | 03/30/2023 |
| 03/30/2023 | Wilkinson Peter J | SVP, Chief Accounting Officer | Payment of Exercise | Common Stock | 526 | $224.70 | $118.2k | | 03/30/2023 |
| 03/30/2023 | Seltz Judith C | EVP, CHRO | Grant | Common Stock | 3.4k | $0.00 | $0 | | 03/30/2023 |
| 03/30/2023 | Seltz Judith C | EVP, CHRO | Payment of Exercise | Common Stock | 1.2k | $224.70 | $261.6k | | 03/30/2023 |
| 03/30/2023 | Summy Amy B. | EVP, Chief Marketing Officer | Grant | Common Stock | 3.2k | $0.00 | $0 | | 03/30/2023 |
| 03/30/2023 | Summy Amy B. | EVP, Chief Marketing Officer | Payment of Exercise | Common Stock | 1.3k | $224.70 | $285.1k | | 03/30/2023 |
|